Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

NEW YORK, Aug. 2, 2020 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),A a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced positive top-line data from its phase 2 EMPhASIS trial of lead asset, IMU-838, the company's selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS).A The study achieved all primary and key secondary endpoints, indicating activity in RRMS patients. In particular, the study metA its primary endpoint, demonstrating a statistically significant reduction in the cumulative number of combined unique active (CUA) magnetic resonance imaging (MRI) lesions up to week 24 in patients receiving 45mg of IMU-838 once daily,A by 62% (p=0.0002), as compared to placebo.A The study also met itsA key secondary endpoint,A showing a statistically significantA reduction inA the cumulative number of CUA MRI lesions for the 30mg once daily dose,A by 70% (p<0.0001),A as compared to placebo.











IMU-838



Placebo



Suppression
of CUA MRI
Lesions



p-value
(1-sided)